Excited to share that Johnson & Johnson Innovative Medicine is collaborating with Odyssey Therapeutics to leverage the power of #artificialintelligence and #machinelearning to advance the discovery and optimization of small molecule medicines against multiple therapeutic targets.
#AI is increasingly playing a key role in #drugdiscovery, enabling us to identify novel targets, more rapidly and efficiently identify the most promising molecules to advance into clinical development, and design and optimize molecules across multiple parameters in ways previously only possible through resource-intensive efforts in the wet lab.
We are excited to leverage this collaboration with Odyssey to complement our own internal discovery efforts – with the goal of developing and delivering potentially game-changing #innovation for patients.
A huge thank you to all those involved in making this collaboration possible – including Gary D. Glick and his fantastic team at Odyssey, as well as John C. Reed and J&J colleagues across our Data Science & Digital Health, Discovery, and J&J Innovation teams, including David Apfel, Michael Bemben, PhD, Julian Bertschinger, Jens Bitsch Norhave PhD MBA, Elena Diez Cecilia, PhD, MBA, Sarah Lively, Tommaso Mansi, Colin Moran, Andrew Peat, Michal Preminger, Emma R Parmee, Chris Picariello, Justin Sheer, Richard Tillyer, Herman van Vlijmen and so many more.
Learn more about this collaboration and its potential impact: https://lnkd.in/eADZ6TfA
Head of Business Development (Practice Groups & Sectors) at Stephenson Harwood LLP
9moReally helpful summary Alice Routh!